Key facts
- This page summarizes John A. Orwin's Form 4 filing for ANAPTYSBIO, INC (ANAB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Sep 2024, 18:45.
John A. Orwin - 15 Sep 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)
- Reporting relationship
- Director
- Issuer ticker
- ANAB
- Reported as of
- 15 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Sep 2024, 18:45:02 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 07 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Loumeau, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John A. Orwin filed Form 4 for ANAPTYSBIO, INC (ANAB) on 17 Sep 2024.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANAB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,300
- Change %
- +64%
- Price
- $0.000000
- Shares after
- 3,335
- Date
- 15 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANAB
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -1,300
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 2,600
- Date
- 15 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,300
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F2
The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.